Neurology focus Target hospitals, clinics, and patient advocacy groups specializing in underserved neurological disorders and rare diseases, highlighting Acadia's FDA-approved therapies for Parkinson's disease psychosis and Rett syndrome as entry points for partnerships, co-promotion, and patient access programs.

Growing pipeline Leverage Acadia's mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis to position additional collaboration opportunities, companion diagnostics, and real-world evidence studies with CROs, biotechs, and payers seeking to expand neurology portfolios.

Financial capacity With substantial revenue and funding, pursue multi-year strategic collaborations, licensing, and equity-linked deals, as well as scale-up manufacturing partnerships to support expanded product availability and new formulations like DAYBUE STIX.

AI and tech Engage in AI-driven drug development and commercial analytics collaborations leveraging Acadia’s recent hire in AI strategy and enablement, as well as their tech stack, to offer advanced data science, market access modeling, and patient recruitment optimization services.

Go-to-market expansion Capitalize on DAYBUE STIX launch momentum and ongoing campaigns such as More to Parkinson's to create co-marketing, patient access, and digital health partnerships, including payer engagement and digital patient support programs.